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switching to a combination therapy from monotherapy, regardless of medical 
conditions. Further research is required to evaluate the possible negative aspects 
of FDC drugs.  
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OBJECTIVES: This study reports the results of an economic model predicting 
differences in lifetime cost of health care services consumed following heart 
valve surgery by prosthesis type. This model examines: Mechanical Valve (MV), 
Stented Tissue (ST) and the emerging Transcatheter Valve (replacement surgery 
only) METHODS: The economic model assumes a 55-year-old valve disease 
patient requiring surgery with a 25 year post-surgery life expectancy. Peer 
reviewed journals provided estimates of complication event rates by prosthesis 
type. The model estimated costs for two possible types of valve replacement 
procedure at year 15 for patients receiving initial ST prosthesis: 1) a second ST 
surgery (ST), or 2) a transcatheter valve in valve (ViV) approach. Average annual 
inflation rate of 3% was used. Clinical events included: initial valve surgery; 
thrombotic events; bleeding events; warfarin and monitoring; echo monitoring; 
paravalular leak; endocarditis; pacemaker insertion following valve surgery; re-
operation due to structural valve deterioration; and clinical complications 
following transcatheter procedures. RESULTS: Cumulative costs were estimated 
to be $124,200 using MV during initial surgery; $183,600 using STs; and $478,048 
using ViV. The MV resulted in lower expected health care costs in every year 
versus either ST approaches. The MV choice at the initial surgery results in a 
lifetime cost saving of $59,400 and $353,882 compared to using STs and ViV, 
respectively. The MV approach obtains the majority of its savings after year 15. 
CONCLUSIONS: Our model estimates changing initial prosthesis choice to the 
MV in the estimated 20,000 ST valve surgeries performed annually in the U.S. 
among patients below age 65 would result in approximately $1.2 billion lifetime 
reduction in direct health care expenditures over the next 25 years, The majority 
of savings occur when these patients would be Medicare Beneficiaries.  
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OBJECTIVES: We examined predictors of high cost for abdominal aortic 
aneurysm (AAA) repair in order to identify patients who are likely to require 
more intensive treatments. In general, younger, healthier patients with 
unfavorable anatomy are good candidates for Open AAA repair while older 
patients with significant comorbidities and favorable anatomy have better 
results when treated with the less invasive endovascular aneurysm repair (EVAR) 
procedure. Indeed, a sizable number of patients present with AAA who could be 
treated safely following either modality. METHODS: A dataset of elective AAA 
repairs totaling 389 Fletcher Allen Health Care patients (230 EVAR, 159 OPEN) was 
analyzed retrospectively over the time period January 1, 2003 through December 
31, 2011. Direct and indirect costs were obtained along with length of stay (LOS) 
and other clinical and behavioral parameters. Models to predict being in the 
upper quartile of cost were developed using logistic regression. RESULTS: 
Significant predictors of being in the upper quartile of costs for Open patients 
were history of treated COPD, previous bypass surgery, transfer from hospital, 
and age >70, with area under ROC=0.726. Predictors for EVAR patients were 
presence of iliac aneurysm(s), CABG/PTCA within the past 5 years, ejection 
fraction ≤30%, on beta blocker, creatinine ≥1.5mg/dl, and current smoker, with 
area under ROC=0.784. For EVAR patients, who had an average LOS of only 1-2 
days, total costs ranged from $21,904 to $47,511. For Open patients, who had an 
average LOS of 5-7 days, these figures ranged from $13,549 to $35,685 in constant 
dollars. CONCLUSIONS: This wide range of total cost invites the introduction of 
resource utilization tools based on cost predictors that can optimize clinical 
outcomes and reduce costs at the individual patient level.  
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OBJECTIVES: Platinum chromium everolimus-eluting stents (PtCr-EES) were 
compared to cobalt chromium everolimus-eluting stents (CoCr-EES) in the 
randomized controlled PLATINUM trial. Clinical outcomes including rates of 
target vessel revascularization (TVR), myocardial infarction (MI), and cardiac 
death have been reported through 2 years (n=1507), with 3 year data to come. An 
economic analysis was performed to assess the cost-effectiveness of PtCr-EES 
versus CoCr-EES accounting for stent reimbursement practice, in which payers 
reimburse by procedure but hospitals bear the direct cost of stents. METHODS: A 
Markov model was used to compare costs from payer (Medicare) and hospital 
perspectives of PtCr-EES versus CoCr-EES over two years, based. The model 
explicitly accounted for costs (2013) of differences in index procedure and long-
term cardiac events. Payer costs for the index procedure were increased only for 
those bailout (unplanned) stents associated with major complicating conditions 
(MCC; aortic dissections or extended length of stay), while hospital costs 
reflected all stents used (bailout or planned). Similarly, those MIs concurrent 
with TVR and all stent thromboses were modeled as MCCs of the TVRs, not 
separate events. RESULTS: PtCr-EES was cost saving versus CoCr-EES by 
$277/patient from a payer perspective, due to reduced costs for bailout stenting 
during the index procedure (3.1% vs. 4.2%) and TVR over 2 years (4.3% versus 
5.4%). Probabilistic sensitivity analysis found PtCr-EES was economically 
dominant (more effective and less costly) in 81% of replications. From a hospital 
perspective, PtCr-EES saved an additional $151/patient in reduced stent 
acquisition costs. A detailed costing analysis would be required to determine 
how much of the $277/patient reduction in reimbursement reflects reduced 
hospital costs, and thus total societal savings. CONCLUSIONS: PtCr-EES was 
found to be cost saving versus CoCr-EES from both payer and hospital 
perspectives, primarily due to reduced TVR over 2 years. Total societal savings 
may be up to $428/patient.  
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OBJECTIVES: We examined the average number of reinterventions, average 
reintervention costs (ARC), and the average total costs (ATC) for the latest 
iteration of a heparin-bonded ePTFE Stent-Graft versus a bare metal stent (BMS) 
in patients treated for atherosclerotic disease of the superficial femoral artery 
(SFA). ATC includes costs for the initial implant, reinterventions, and follow-up 
care. METHODS: As previously reported by Saxon (2011) and Ansel (2011), two 
independent clinical studies of the Stent-Graft were recently completed. One-
year results from the multicenter, single-arm, VIPER trial were compared to the 
one-year results of the BMS arm from the three-year, multicenter, randomized 
VIBRANT trial. The Stent-Graft used in the VIPER trial is the latest iteration of the 
device in use today. Patient characteristics were similar in both trials. Cost data 
from the Centers for Medicare and Medicaid Services was used to estimate ARC 
and ATC for all patients, and secondarily, for patients oversized ≤20% at the 
proximal edge of the Stent-Graft (instructions for use recommend 5-20% 
oversizing). RESULTS: The Stent-Graft group trended toward fewer 
reinterventions per patient than the BMS group (0.36 vs. 0.63, P=0.15), lower ARC 
($3,143 vs. $4,346, P=0.38), and higher ATC ($16,482 vs. $14,987, P=0.36) through 
one year follow-up. Patients oversized ≤20% trended toward fewer 
reinterventions per patient (0.21 vs. 0.63, P=0.08), lower ARC ($1,588 vs. $4,346, 
P=0.05), which was statistically significant, and lower ATC ($14,524 vs. $14,987, 
P=0.78) versus the BMS. CONCLUSIONS: Based on the comparison of one-year 
follow up data, the Stent-Graft trended toward reducing reinterventions and ARC 
for all patients being treated for atherosclerotic SFA disease compared to BMS. 
When oversized ≤20% at the proximal edge, the Stent-Graft reduced ARC 
(statistically significant finding) and trended toward reducing reinterventions 
and ATC. Long-term follow up will be needed to measure the benefits beyond 
one year for all patients.  
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OBJECTIVES: Estimate the real-world economic impact of switching from 
metoprolol, the most commonly prescribed β-blocker for hypertension in the US, 
to nebivolol, a novel well-tolerated β-blocker with high β1 selectivity and 
vasodilatory properties, for hypertension treatment. METHODS: Retrospective 
database analysis with a pre and post study design was conducted using 
MarketScan database (2007-2011). Hypertensive patients continuously treated 
with metoprolol for at least six months (pre-period) and then switched to 
nebivolol for at least six months (post-period) were identified. The first nebivolol 
dispensing date was defined as the index date for switching. Data were collected 
for the two six-month periods pre- and post- switching. Monthly health care 
resource utilization and health care costs pre and post switching were calculated 
and compared using Wilcoxon and paired t-tests. Medical costs at different years 
were inflated to the 2011 dollar using medical component consumer price index. 
RESULTS: A total of 2259 patients, with a mean age of 60, met the selection 
criteria. Among them, 52% were male, 37% had cardiovascular (CV) disease. After 
patients switched to nebivolol, there were statistically significant reductions in 
the number of all-cause hospitalization (p<0.01), CV related hospitalization 
(p<0.01), outpatient visits (p<0.01), and CV related emergency room (ER) visits 
(p=0.01). Monthly inpatient costs reduced $106 (p<0.01), while monthly drug cost 
increased $49 (p<0.01). There were reductions on costs of outpatient and ER 
visits, but the differences were not statistically significant. Overall health care 
cost reduced $63 per patient per month. Sensitivity analysis on length of 
medication exposure found similar results. CONCLUSIONS: This real-world 
study finds that patients who switched from metoprolol to nebivolol had a lower 
overall health care cost after switching.  
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OBJECTIVES: To evaluate health care costs following acute coronary syndromes 
(ACS) in patients with/without recurrent cardiovascular events (CVEs). 
METHODS: Patients with ≥1 ICD-9 CM codes for acute myocardial infarction 
(410.xx) or unstable angina (411.1x) during ACS hospitalization were identified 
from the HealthCore Integrated Research Database January 1, 2006 to September 
30, 2011 (index event date defined as first ACS hospitalization date). Patients 
with <12 months pre/post-index plan eligibility or <18 years old were excluded. 
Recurrent CVEs were defined as myocardial infarction, non-fatal stroke or 
coronary heart disease-related mortality. Total and CV-related hospitalization 
costs following index ACS were evaluated in patients with/without recurrent 
CVEs, adjusting for demographic characteristics, comorbidities, treatment 
utilization and index ACS characteristics. RESULTS: Of 140,903 US patients, 22.0% 
had ≥1 subsequent CVE during follow-up. Patients with versus without recurrent 
CVEs were older - and had more comorbidities. Mean (median) follow-up was 2.0 
(1.6) and 1.9 (1.5) years in patients with and without recurrent CVEs, respectively. 
Mean (median) length of stay for index ACS hospitalization was longer in 
patients with versus without recurrent CVEs. Mean (median) 1-year post-index 
total and CV-related cost were higher in patients with versus without recurrence 
($41,478 [$17,474] and $34,094 [$10,057] versus $30,608 [$17,241] and $23,613 
[$10,336]; p<0.001). Inpatient hospitalization costs were the major driver of total 
expenditures, comprising 76% and 72% of total costs in patients with versus 
without recurrence, respectively. Mean 2- and 3-year post-index total and CV-
related costs were also significantly higher in patients with recurrent CVEs (2-
year: $27,746 and $20,572 vs. $18,707 and $12,794; 3-year: $21,880 and $15,260 vs. 
$14,438 and $9,049; p<0.001). CONCLUSIONS: Following ACS hospitalization, 
patients with recurrent CVEs incurred higher 1-, 2- and 3-year post-index event 
costs compared those without recurrence, underscoring the need to focus on the 
prevention of subsequent adverse CVEs following ACS to improve patient 
outcomes and reduce total health care cost.  
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OBJECTIVES: An increasing proportion of coronary artery bypass grafting (CABG) 
surgery is performed with concomitant valve repair or replacement surgery, and 
complications related to these procedures can have significant impact on 
patients and health care systems. This study quantifies the incidence and 
clinical and economic burden of complications associated with CABG, valve and 
combined (CABG and valve) surgery in the US. METHODS: Premier Perspective 
database was used to identify patients having CABG and/or valve surgery 
between Jan 2008 to Dec 2011. The study complications were postoperative 
infection, septicemia, postoperative stroke, postoperative adult respiratory 
distress syndrome, new-onset hemodialysis, reoperation, respiratory 
complication, cardiac complication, and hemorrhage. Both surgeries and 
complications were identified by ICD-9 codes. This study investigated (1) overall 
incidence rate of any study complication, (2) differences in length of stay (LOS), 
and (3) total inpatient costs for patients with and without complications during 
index and readmission within 30 days across three procedures. For multivariate 
adjustments, Gamma-distributed generalized linear model (GLM) and Poisson-
distributed GLM models were used. RESULTS: Of 100,601 patients who 
underwent CABG alone, 31,903 (31.7%) had any study complications during their 
index or readmitted stay. Patients with valve alone or combined surgery had 
higher incidence of complications: 38.2% and 47.3% (p<0.01 for both), 
respectively. Complications in CABG incurred additional average LOS of 4.8 days 
(p<0.01) and additional average hospital cost of $14,699 (p<0.01) over CABG 
patients not experiencing complications, while complications in valve alone and 
combined surgery incurred an additional 6.8 days, $23,464 and 6.7 days, $24,985 
respectively. CONCLUSIONS: Results showed complications in CABG and/or 
valve surgery increase clinical and economic burden by 0.41 to 0.60 times in 
terms of additional LOS and hospital costs. The burden increases significantly 
when a patient has combined procedures. The results highlight the potential 
opportunity for cost reduction by preventing the complications associated with 
CABG and/or valve surgeries.  
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OBJECTIVES: Cost of illness in ischemic stroke has historically been reported as 
direct total health care cost, not compared to an equally ill, non-stroke, control 
group. This methodology likely overestimates cost and may affect national 
burden of illness estimates and cost effectiveness comparisons. The magnitude 
of the over-estimation is not known. The objective of this study is to estimate 
the 1-year marginal cost of ischemic stroke in SC Medicare beneficiaries and 
examine the impact of total versus marginal cost reporting on overall US stroke 
cost estimates and on the distribution of expenditures of inpatient care and 
rehabilitation. METHODS: Cost of illness was estimated from a Medicare cost 
perspective for ischemic stroke in South Carolina. Stroke patients were matched 
1:2 to non-stroke beneficiaries using nearest-neighbor propensity score 
matching. Standard Medicare analytic files for all beneficiaries in SC in 2004 and 
2005 were summed for the year following their index ischemic stroke or to death. 
The total study sample size was 8928. RESULTS: The use of a marginal costing 
approach produced lower estimates than the average total costing method. The 
2004 marginal costs of stroke were $26.9 million, while the average cost estimate 
was $81.3 million, a difference of $54.4 million. Average total cost includes 
expenditures for comorbid conditions which are common in patients with 
stroke. Cost of stroke for the US in 2012 would be overestimated by $4.89 billion 
if this difference is generalized to national estimates. Furthermore, the 
proportion of stroke costs attributable to rehabilitation services would change 
from 13.7% based on mean cost, to 29.3% using marginal estimates. 
CONCLUSIONS: Using a marginal costing approach to estimate health care costs 
for conditions common in patients with a high prevalence of comorbid 
conditions is essential for accurate estimation of burden of illness, as well as 
estimating in-hospital and follow-up cost distributions correctly.  
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OBJECTIVES: To estimate the costs-of-disease and direct cost components of 
thromboembolic complications associated with AF and the side-effects related 
with anticoagulant treatment, in Turkish setting. METHODS: A panel consisting 
of experts on cardiology, hematology, pulmonology and neurology, held a 
meeting to discuss the disease management processes of stroke, SE, IC bleeding 
and EC bleeding. They reviewed the global and local literature and guidelines, 
and also they discussed the spectrum of local clinical practices that are 
performed frequently. All cost components, including medications, surgical 
treatment, hospitalization, out-patient follow-up procedures and rehabilitation 
services were reviewed. September 2012 local prices for medications and 
procedures were used as sources. Mid-2012 USD currency rate was used. 
RESULTS: The cost of SE was estimated as 431 USD/event (70% non-
pharmacologic treatment cost). The cost of acute management of stroke was 
calculated as 2,517 USD, of which 76% was caused by hospital stay. The annual 
cost of follow-up of stroke patients was 799 USD/year. The source of almost half 
(48%) of the cost was non-pharmacologic treatment (namely neurologic 
rehabilitation). The cost of major EC bleeding was 1014 USD/event (48% hospital 
stay cost) and the cost of minor EC bleeding is 49 USD/event (~100% hospital stay 
cost). The cost of acute management of IC bleeding was calculated as 6166 
USD/event (86% hospital stay cost). The annual cost of follow-up of patients with 
IC bleeding was 728 USD/year (52% non-pharmacologic treatment cost). 
CONCLUSIONS: The costs of thromboembolic complications in AF patients are 
quite high. The acute events of stroke or IC bleeding are quite costly, and 
additional costs continue to happen due to treatment of neurologic disabilities 
caused by the primary event. Therefore, the economic burden of these 
thromboembolic events might be well reduced, if the prevention of these events 
could be prevented in AF patients.  
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OBJECTIVES: Venous thromboembolism (VTE), a condition that includes deep 
vein thrombosis (DVT) and pulmonary embolism (PE) is associated with major 
morbidity and mortality and causes huge economic burden. The purpose of this 
study was to evaluate direct and indirect costs of patients with VTE in China, 
producing an average cost per patient per year. METHODS: A cost-of-illness 
analyses was performed. The economic data was collected from an observational 
retrospective study. We recruited 154 patients diagnosed with VTE in Beijing, 
Shanghai and Guangzhou between October 2012 and December2012. Patients or 
their carers completed a questionnaire about resource utilization and 
absenteeism from work in the past year by an interview. Direct medical costs 
included outpatient visit, hospitalization,, ambulatory, drug, diagnostic tests, 
and physiotherapy costs. Indirect costs were estimated using a human capital 
approach. All costs referred to 2011. RESULTS: Among 154 patients, DVT 
accounted for 85.7%,51.95% were female and the mean age was 61.5±12.4. 96.8% 
patients have at least one kind of health insurance. From the societal 
perspective, total costs per patient over 1 year amounted to Chinese Yuan (CNY) 
21484 (median: CNY14039, IQR: CNY6714-CNY32036). The direct medical costs 
were CNY15899 accounting for 74% of the total. The informal care costs were 
CNY3623 accounting for 16.9% of the total. And the indirect costs were CNY1678 
accounting for 7.8%. CONCLUSIONS: The economic burden of VTE in China is 
considerable. The primary burden on patients was due to the direct medical 
costs.  
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OBJECTIVES: Atrial fibrillation (AF) increases the risk of stroke 5-fold and may be 
responsible for larger and more disabling strokes than those without AF which 
increase the associated costs of care. The purpose of this study was to evaluate 
